MedKoo Cat#: 565540 | Name: FT011
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

T011 is an anti-inflammatory and anti-fibrotic agent that has been reported to attenuate organ damage in diabetic rats with cardiomyopathy and nephropathy. In diabetic rats, FT011 reduced retinal leukostasis, microglial density and mRNA levels of intercellular adhesion molecule-1 (ICAM-1). In Müller cells, FT011 reduced diabetes-induced gliosis and vascular endothelial growth factor (VEGF) immunolabeling and the hyperglycaemic-induced increase in ICAM-1, monocyte chemoattractant protein-1, CCL20, cytokine-induced neutrophil chemoattractant-1, VEGF and IL-6.

Chemical Structure

FT011
FT011
CAS#1001288-58-9

Theoretical Analysis

MedKoo Cat#: 565540

Name: FT011

CAS#: 1001288-58-9

Chemical Formula: C20H17NO5

Exact Mass: 351.1107

Molecular Weight: 351.36

Elemental Analysis: C, 68.37; H, 4.88; N, 3.99; O, 22.77

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 450.00 2 Weeks
200mg USD 750.00 2 Weeks
500mg USD 1,650.00 2 Weeks
1g USD 2,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
FT011; FT0 11; FT0-11; FT-11; SHP-627; SHP627; SHP 627; asengeprast
IUPAC/Chemical Name
2-(3-Methoxy-4-propargyloxycinnamoyl)aminobenzoic acid
InChi Key
UIWZIDIJCUEOMT-PKNBQFBNSA-N
InChi Code
InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)/b11-9+
SMILES Code
O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC=C(OCC#C)C(OC)=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 351.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DJ, Wilkinson-Berka JL. FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS One. 2015 Jul 29;10(7):e0134392. doi: 10.1371/journal.pone.0134392. eCollection 2015. PubMed PMID: 26222724; PubMed Central PMCID: PMC4519240. 2: Lau X, Zhang Y, Kelly DJ, Stapleton DI. Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia. 2013 Mar;56(3):675-9. doi: 10.1007/s00125-012-2805-9. Epub 2012 Dec 16. PubMed PMID: 23242170. 3: Zhang Y, Elsik M, Edgley AJ, Cox AJ, Kompa AR, Wang B, Tan CY, Khong FL, Stapleton DI, Zammit S, Williams SJ, Gilbert RE, Krum H, Kelly DJ. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. Int J Cardiol. 2013 Sep 30;168(2):1174-85. doi: 10.1016/j.ijcard.2012.11.067. Epub 2012 Dec 6. PubMed PMID: 23219315. 4: Gilbert RE, Zhang Y, Williams SJ, Zammit SC, Stapleton DI, Cox AJ, Krum H, Langham R, Kelly DJ. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One. 2012;7(10):e47160. doi: 10.1371/journal.pone.0047160. Epub 2012 Oct 10. PubMed PMID: 23071743; PubMed Central PMCID: PMC3468513. 5: Zhang Y, Edgley AJ, Cox AJ, Powell AK, Wang B, Kompa AR, Stapleton DI, Zammit SC, Williams SJ, Krum H, Gilbert RE, Kelly DJ. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail. 2012 May;14(5):549-62. doi: 10.1093/eurjhf/hfs011. Epub 2012 Mar 14. PubMed PMID: 22417655.